We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Inotiv Inc (NOTV) NPV

Sell:$6.00 Buy:$10.75 Change: $0.21 (2.19%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.21 (2.19%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.21 (2.19%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Inotiv, Inc. is an international contract research company that is focused on providing drug discovery and development services and analytical instruments. The Company focuses on providing drug developers with scientific research and analytical instrumentation. The Company operates through two segments, including Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance and quality control testing. The Research Products segment offers two principal product lines, including analytical products and in vivo sampling products. Analytical products consist of liquid chromatographic and electrochemical instruments with associated accessories. In vivo sampling products consist of the Culex family of automated in vivo sampling and dosing instruments.

Contact details

2701 Kent Ave
United States
+1 (317) 4634527

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$243.93 million
Shares in issue:
25.52 million
Life Sciences Tools & Services
United States
US dollar

Key personnel

  • Robert Leasure
    President, Chief Executive Officer, Director
  • Beth Taylor
    Chief Financial Officer, Vice President - Finance
  • Glenn Washer
    Group President, Safety Assessment
  • John Beattie
    Chief Operating Officer
  • James Harkness
    Chief Operating Officer - Research Models and Services
  • William Pitchford
    Chief Human Resource Officer
  • Adrian Hardy
    Executive Vice President
  • Philip Downing
    Senior Vice President - Preclinical Services
  • Mark Bibi
    General Counsel, Secretary
  • John Sagartz
    Chief Strategy Officer, Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.